CMTM7 and breast cancer: To further validate the methylated regulation of CMTM7 promoter region, the DNA methyltransferases (DNMT) inhibitor AZA was used for treating breast cancer cells at the concentrations of 1.0, 1.5, 2.0, and 2.5 μM.